Antibodies to synthetic joining segment peptide of the T-cell receptor a-chain : Serological cross-reaction between products of T-cell receptor genes , antigen binding T-cell receptors , and immunoglobulins ( adl heterodimer / VH related T-celi products / Immunoblot )
S. Schluter,J. Marchalonis
Abstract:Immunoglobulin light and heavy chains show sequence homology to one another and to the polypeptide chains of putative T-cell receptors in the J (joining) segment of the variable region. Antibodies produced against synthetic peptides corresponding to the entire JH1 region and part of the diversity segment region cross-react serologically with products of normal T cells and monoclonal T-cell lines. In this study we generate immune affinity-purified rabbit antibodies to a synthetic 16-mer peptide consisting of the entire JT sequence and part of the T-cell diversity sequence corresponding to these segments of the human putative T-cell receptor (3 gene YT35. Both free peptide and peptide coupled to bovine serum albumin as carrier were found to stimulate the production of antibody. The immune affinity-purified anti-JT peptide antibodies bound to intact immunoglobulin and to' light and heavy chain as detected by enzyme-linked immunosorbent assay and by imm munoblot transfer. The antibody reacted by these techniques with membrane components of the human monoclonal amplifier T-cell MOLT-3 and the murine suppressor T-cell WEHI-7. The component detected in the MOLT-3 cell corresponded to the (-chain of the a/( heterodimer putative T-cell receptor; whereas the molecule detected in the WEHI-7 line had properties corresponding to those of antigen-specific T-cell suppressor receptors. The molecular size of this component under reducing conditions was approximately 68 kDa and the intact form had an apparent mass of 140 kDa. These results provide direct proof of serological cross-reaction among products of putative T-cell receptor genes, antigen-binding T-cell receptors, and immunoglobulins, thereby supporting the concept that antigen receptors of T lymphocytes all represent new immunoglobulin translocons. Immunoglobulin variable (V) regions provide the amino acid residues that form the combining site for antigen. These molecules express serologically detectable determinants correlated with complementarity determining residues-i.e., idiotypes (1)-and framework regions-i.e., allotypes (2)that also occur on antigen-binding molecules of thymusderived lymphocytes (3-6). Three types of putative T-cell receptor genes-a (7), 13 (8, 9), and y (10)-have been characterized in some detail. The 1B gene cluster, in particular, contains structures comparable to the V region segment of immunoglobulin heavy chains (Vat), diversity segments (D13), joining segments (Jo), and constant (C13) regions, and strong homology with immunoglobulin V regions is observed for the predicted product of these genes (11). Serological data substantiating the homology between T-cell receptors and immunoglobulin heavy chain V regions (VH) has been obtained using antibodies directed against entire VH fragments (12) and antibodies against a synthetic peptide corresponding to the JH and part of the D sequence of classical immunoglobulin (13). In this paper we test directly the relationship between putative T-cell receptor of the 13 type, antigen-binding T-cell receptors that are serologically related to immunoglobulin VH regions (VTMs) (14) and conventional immunoglobulin by generating antibodies against a synthetic peptide of the residues corresponding to the entire Jo and part of the Dp3 predicted from the sequence of a human (3 gene (8). We report that affinity-purified rabbit antisera to this peptide cross-react with immunoglobulin light and heavy chains as would be predicted from sequence homologies and, furthermore, allow the discrimination of products corresponding to a/,B heterodimers and antigenbinding VTM products when comparing cloned T-cell lines of distinct phenotype. MATERIALS AND METHODS Cell Lines and Cell Extracts. The BALB/c-derived monoclonal T-lymphoma cell line of suppressor phenotype WEHI7 was grown in RPMI 1640 supplemented with 5% (vol/vol) Nu Serum (Collaborative Research, Waltham, MA) at 37C and 94% air/6% CO2 atmosphere. For extraction of membrane products, lymphomas, induced in BALB/c mice by subcutaneous injection of 106 WEHI-7 cells, were excised 2 weeks later. The lymphoma tissue was pulverized in liquid nitrogen and then extracted with 70% (vol/vol) formic acid as described (13, 15). A deoxycholate extract prepared from the monoclonal leukemic human amplifier T-cell line MOLT-3 as described by Bonewald et al. (16) was a gift of An-Chuan Wang (Department of Basic and Clinical Immunology and Microbiology, Medical University of South Carolina). VTM material was prepared from the WEHI-7 formic acid extract by affinity chromatography on rabbit anti-VT Sepharose 4B as described (15). T-Cell Receptor (3-Chain J Segment (JT) Synthetic Peptide. The peptide was custom synthesized by Peninsula Laboratories (Belmont, CA). Its sequence, Ala-Asn-Tyr-Gly-TyrThr-Phe-Gly-Ser-Gly-Thr-Arg-Leu-Thr-Val-Val, corresponds to the entire JP and part of the D13 region of human (3 chain as predicted from the DNA sequence of the YT35 13 gene clone (8). Purity was confirmed by thin layer chromatography, paper electrophoresis, and reverse phase HPLC. The amino acid analysis is as follows (theoretical values in parentheses): Arg, 1.11 (1); Asp, 0.88 (1); Thr, 2.77 (3); Ser, 0.66 (1); Gly, 2.98 (3); Ala, 1.04 (1); Val, 2.10 (2); Leu, 0.93 Abbreviations: VTM, T-cell receptors bearing Ig heavy chain variable region determinants; BSA, bovine serum albumin; JT, joining segment of the T-cell antigen receptor; V, variable; D, diversity; J, joining. 1872 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Proc. Natl. Acad. Sci. USA 83 (1986) 1873 (1); Tyr, 1.74 (2); Phe, 1.02 (1). Insulin A chain, a 21-residue peptide, was a gift of Erika Bullesbach (Department of Biochemistry, Medical University of South Carolina). Production of Antisera. For immunization of rabbits, peptides were coupled to bovine serum albumin (BSA) by glutaraldehyde treatment. To peptide (5 mg) and BSA (5 mg) suspended in 0.1 M sodium phosphate buffer (pH 7.5) was added 10 A.l of 12.5% (vol/vol) glutaraldehyde. After 90 min incubation at room temperature 100 tkl of 1 M ethanolamine (pH 8) was added, and the conjugate was purified on Sephadex G-50. A coupling efficiency of50% was determined by including in the reaction a trace amount of peptide labeled with 125I by the chloroamine-T method (17). Rabbits were injected subcutaneously with 400 ,ug of conjugate in complete Freund's adjuvant and subsequently with 2 injections of 400 Ag of conjugate in incomplete Freund's adjuvant at monthly intervals. Immunization with free peptide was by the same procedure by using 500 gg per injection. Blood was drawn after 10 weeks. Immunoglobulins. Murine IgG was prepared from pooled normal mouse serum by treatment with octonoic acid as described by Steinbuck and Andran (18). Dog IgG, prepared using protein A-Sepharose (Pharmacia) (19), was a gift of Gregory W. Warr (Department of Biochemistry, Medical University of South Carolina). Human IgG was purchased from Cappel (Cooper Biomedical, Malvern, PA). Coupling of Peptides to Sepharose. Peptide (5 mg) in 0.1 M Na2CO3 (pH 10.5) was incubated with epoxy-activated Sepharose-4B (Pharmacia) at 37°C for 24 hr, washed, and then incubated with 1 M ethanolamine (pH 8) overriight to block unreacted sites. The procedure was essentially as recommended by the manufacturer. Immunobinding Assays. ELISAs were performed as described (13, 15) using diluents containing 1% BSA. Plates were coated with free peptide by the method of Green et al. (20). Immunoblot analyses were performed as described (13) except that the quenching and diluent solutions were 1% fish gelatin (Norland Products, New Brunswick, NJ) (21), 0.05% Tween 20 in phosphate-buffered saline (PBS, pH 7.4).